Skip to main content
Journal ArticleOPEN ACCESS

Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: Directions from COMPASS?

European Heart Journal (2019) 40(46) 3779-3781
DOI: 10.1093/eurheartj/ehz517
4Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.

Cite

CITATION STYLE

APA

Kozieł, M., & Lip, G. Y. H. (2019). Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: Directions from COMPASS? European Heart Journal, 40(46), 3779–3781. https://doi.org/10.1093/eurheartj/ehz517

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free